[
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Continuous and categorical outcome variables were compared across groups (buspirone and placebo) using independent t tests and chi-squared tests, respectively.Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Subjective Opiate Withdrawal Scale Total Scores\nLinear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Linear mixed-model analyses determined there was no significant effect of study group on SOWS Total score, but there was a significant effect of day, F(18, 245) = 6.4, p < .001, and group × day, F(18, 245) = 1.8, p = .02 (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]